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Lipoic acid supplementation prevents angiotensin II–induced
renal injury.
Background. Angiotensin II (Ang II)–induced renal injury
is associated with perivascular inflammation, cell proliferation,
and increased superoxide production in the vascular wall. We
tested whether lipoic acid, an endogenous antioxidant, protects
against the Ang II–induced inflammatory response and end-
organ damage.
Methods. Light microscopy, immunohistochemistry, electro-
phoretic mobility shift assay, Northern blots, and high-pressure
liquid chromatography (HPLC) were used in kidneys from
double transgenic rats (dTGR) harboring human renin and
angiotensinogen genes and normotensive Sprague Dawley (SD)
rats. The effects of lipoic acid supplementation for three weeks
were examined in dTGR and SD rats.
Results. Lipoic acid effectively prevented Ang II-induced
glomerular and vascular damage in the kidneys and completely
prevented the development of albuminuria. Ang II–induced
leukocyte infiltration and cell proliferation in the kidney were
attenuated. The redox-sensitive transcription factors nuclear
factor (kappa) B (NF-B) and activator protein-1 (AP-1) in
the kidneys were increased in dTGR compared with SD, and
were effectively reduced. Renal glutathione levels were much
higher in dTGR than in SD, while the opposite was true for
cysteine levels. These results suggested increased renal gluta-
thione oxidation in dTGR, leading to cysteine shortage. Lipoic
acid partly prevented renal cysteine depletion and increased
hepatic cysteine and glutathione concentrations. This effect
was accompanied by increased hepatic gamma-glutamylcys-
teine synthetase mRNA expression.
Conclusion. Our in vivo results suggest that lipoic acid pro-
tects against Ang II–induced renal injury through anti-inflam-
matory/antioxidative mechanisms. The effects are associated
with decreased NF-B and AP-1 activation, as well as improved
thiol homeostasis.
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scription factor NF-B, transcription factor AP-1.
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Reactive oxygen species (ROS) have been implicated
in the pathogenesis of cardiovascular diseases [1]. ROS
influence signal transduction pathways, cellular growth,
and posttranslational protein modifications [2, 3]. Sev-
eral hormone-sensitive enzymes, such as nicotinamide
adenine dinucleotide phosphate [NAD(P)H] oxidase, xan-
thine oxidase, cyclooxygenases, nitric oxide (NO) syn-
thases, heme oxygenases, and peroxidases generate ROS
[2]. ROS are important in the pathogenesis of angioten-
sin (Ang) II–induced hypertension and vascular damage
[4]. Furthermore, Ang II induces oxidative stress and
superoxide formation primarily through activation of
NAD(P)H oxidase in the vascular smooth muscle cells
and myocytes [4, 5].
Intra- and extracellular defense systems protect the
organism from deleterious effects of ROS. Glutathione
sulfhydryl (GSH) is the key molecule in one of the most
important antioxidant systems and helps to maintain the
intracellular redox state by providing a thiol group [6].
GSH is made in two consecutive adenosine triphosphate
(ATP)-requiring enzymatic reactions in which glutamate
and cysteine are first ligated and glycine is added. Cys-
teine supply is often rate limiting; however, transcriptional
and posttranscriptional regulation also occur [7]. Boosting
GSH levels has been attempted with various compounds
[8]. Lipoic acid (6,8-thioctic acid) is promising in this
regard [9], as it is a sulfur-containing coenzyme required
for the mitochondrial dehydrogenase reactions leading
to ATP formation [10–12]. Morikawa et al [13] recently
identified a mouse cDNA encoding a lipoic acid synthase
located in the mitochondria. Lipoic acid and the reduced
form, dihydrolipoate, are potent natural antioxidants both
in fat- and water-soluble media [10, 12, 14]. Lipoic acid
reacts with superoxide, hydroxyl radicals, hypochlorous
acid, peroxyl radicals, and singlet oxygen. Lipoic acid
also recycles vitamin C, vitamin E, and increases intracel-
lular glutathione concentrations. The antioxidative effect
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of lipoic acid may also be partially medixnated by transi-
tion metal chelation, modification of the redox status of
thiol-containing proteins, and by the inhibition of redox-
sensitive nuclear transcription factors [10–17]. Hagen et al
[18, 19] reported that dietary lipoic acid supplementation
improves mitochondrial function, decreases oxidative
stress, and increases metabolic rate in aging rats. Lipoic
acid supplementation ameliorated hypertension, insulin
resistance, and diabetes-associated renal damage [20–22].
Protection against deoxycorticosterone acetate (DOCA)-
salt–induced renal and vascular injuries has also been
reported [23]. We investigated the effectiveness of di-
etary lipoic acid supplementation in the prevention of
complications associated with Ang II production in a
double transgenic rat (dTGR) model that featured oxi-
dative stress [24–28].
METHODS
Experimental animals, drug treatments, and
sample preparation
We used 25, 4-week-old male dTGR and 10 age-
matched normotensive Sprague Dawley (SD) rats, de-
scribed elsewhere [29, 30]. The protocols were approved
by the Animal Experimentation Committee of the Uni-
versity of Helsinki, Finland, whose standards correspond
to those of the American Physiological Society. The rats
had free access to chow (NaCl 0.8%) and drinking water.
dTGR and normotensive SD control rats were divided
into three groups: (1) dTGR control group (N  15);
(2) dTGR  lipoic acid group (N  10); and (3) SD
control group (N  10). The cardiovascular and renal
effects of lipoic acid were also examined in normotensive
SD rats (lipoic acid–treated SD rats, N  6; control SD
rats, N 6). (R)--lipoic acid (Sigma Aldrich Co., Cam-
bridgeshire, UK) was mixed in the food (0.5% weight/
weight) to produce an approximate daily dose of 350
mg/kg and given for three weeks. This dietary lipoic acid
concentration has produced several beneficial effects in
previous rat experiments [18, 31]. Systolic blood pressure
was measured by using a tail cuff blood pressure analyzer
(Apollo-2AB Blood Pressure Analyzer, Model 179-
2AB, IITC Life Science, Woodland Hills, CA, USA).
At 7 weeks of age, rat urines were collected over 24
hours in metabolic cages. Rats were then decapitated;
the heart and kidneys were removed, washed with ice-
cold saline, blotted dry, and weighed. Tissue samples
were snap-frozen in liquid nitrogen and samples for im-
munohistochemistry in isopentane (35C). All samples
were stored at 80C until assayed. Urinary albumin
was measured by enzyme-linked immunosorbent assay
(ELISA) using rat albumin as a standard (Celltrend,
Luckenwalde, Germany).
Renal and cardiac morphology
Our histologic techniques are described elsewhere [32].
We relied on a quantitative grading scale for kidneys,
viewed by a pathologist unaware of the regimens, as fol-
lows: (0) normal arteriologlomerular unit with open capil-
lary lumens and a normal afferent arteriole. Arcuate and
interlobular vessels normal. No tubular atrophy, intersti-
tial inflammation, or interstitial fibrosis; (1) slight thick-
ening of the media of the afferent arteriole. Some mesan-
gial thickening. Open capillary lumens in the glomerulus.
Patchy atrophy of tubular epithelium. Small interstitial
fibrotic scars. Minimal medial thickening in larger ves-
sels. No signs of inflammation; (2) marked mesangial
thickening partly collapsed capillaries in the glomerulus.
Occasional arteriolar thickening. Diffuse tubular atro-
phy and small interstitial fibrotic scars. Clear medial
thickening in larger vessels. Occasional inflammatory in-
filtrate in the interstitium; (3) necrotic arterioglomerular
units with medial and intimal thickening of the arteriolar
wall. Diffuse tubular atrophy with proteinaceous casts,
patches of interstitial fibrosis, sometimes fibrinoid necro-
sis of larger vessels. Inflammatory infiltrate in the inter-
stitium; (4) necrotic arterioglomerular units with marked
cellular crescents. Concentric hypertrophy and necrosis
of afferent arteries. Fibrinoid necrosis and occlusion of
the interlobular and arcuate arteries with thrombotic
material. Atrophic and necrotic tubules. Evident intersti-
tial fibrosis. Strong interstitial inflammation.
Furthermore, the hearts, arteries, and ventricular fi-
brous tissue formation were also evaluated in a blinded
fashion [33]. Each sample was scored from 0 to 3 according
to morphologic changes as follows: (0) epicardial vessels
normal. No excessive ventricular connective tissue forma-
tion; (1) normal intima. Media slightly thickened or nor-
mal. Slight increase of connective tissue around the epi-
cardial and intramuscular arteries; (2) normal intima.
Clear medial thickening and adventitial scarring in epi-
cardial and intramuscular arteries. Patchy increase of
slender connective tissue bundles; (3) normal intima. Clear
medial thickening and adventitial scarring in epicardial
and intramuscular arteries. Evident myocardial scars.
Immunohistochemistry
For immunohistochemistry, frozen kidneys were pro-
cessed and semiquantitative scoring of inflammatory
cells was performed as previously described in detail
[25, 26]. The relative amount of positive labels per sam-
ple was determined with computerized densitometry
(Leica IM500 and Leica QWIN software; Leica Micro-
systems AG, Heerbrugg, Switzerland). Primary mono-
clonal antibodies against rat ED-1, CD-4, and CD-8 (Sero-
tec, Ltd., Oslo, Norway) and peroxidase-conjugated rabbit
anti-mouse secondary antibodies (DAKO A/S, Glostrup,
Denmark) were used. Proliferating cell nuclear antigen
(PCNA) was detected by using a polyclonal mouse anti-
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PCNA antibody (Stressgen Biotechnologies Corp., Vic-
toria, British Columbia, Canada).
Electrophoretic mobility shift assay
Tissue preparation for electrophoretic mobility shift
assay (EMSA) was performed as described earlier [34].
Nuclear extracts (5 g) were incubated in binding re-
action medium with 0.5 ng of 32P-dATP end-labeled oligo-
nucleotide containing the NF-B binding site from the
major histocompatability complex (MHC)-enhancer (H2K,
5-GAT CCA GGG CTG GGG ATT CCC CAT CTC
CAC AGG). Oligonucleotides were synthesized by Bio-
Tez (BioTez, Berlin, Germany). For AP-1, double-
stranded oligonucleotides containing the consensus se-
quence for AP-1 (Santa Cruz, CA, USA) 5-GAT CGA
ACT GAC CGC CCG CCG CCC GT-3) were radio-
labeled with 	-32P with the use of T4 polynucleotide
kinase by standard methods and purified on a column.
The DNA-protein complexes were analyzed on a 5%
polyacrylamide gel 0.5% Tris buffer, dried, and auto-
radiographed. In competition assays, 50 ng unlabeled H2K
or AP-1 oligonucleotides were used.
Determination of tissue glutathione homeostasis
The concentration of thiol compounds glutathione and
cysteine in the liver and kidney was determined fluoro-
metrically after labeling with monobromobimane and
separating various thiols on an HPLC column [35]. The
gene expression of gamma-glutamylcysteine synthetase
(gammaGCS), the rate-limiting enzyme for glutathione
synthesis, was determined by Northern blot as described
in detail elsewhere [36]. Briefly, total RNA was isolated
from kidney samples using Rneasy mini kit (Qiagen
GmbH, Hilden, Germany) and fractionated on agarose/
formaldehyde gel. Following transfer onto nylon filters
(Hybond-N, Amersham Pharmacia Biotech, Uppsala,
Sweden), the blots were hybridized using standard meth-
ods with 32P-labeled complementary RNA probe for
gamma-GCS heavy and light chain. Probes for ribosomal
S18 were used for normalization.
Statistics
Data are presented as mean
 standard error of mean
(SEM). Statistically significant differences in mean val-
ues were tested by analysis of variance (ANOVA) and
Fisher’s test. The differences were considered significant
when P  0.05. The data were analyzed using SYSTAT
statistical software (SYSTAT, Inc., Evanston, IL, USA).
RESULTS
Effects of lipoic acid on albuminuria, blood pressure,
and cardiac hypertrophy
Untreated dTGR developed pronounced albuminuria,
which was 150-fold higher than urinary albumin excre-
tion in normotensive SD rats (Fig. 1A). Systolic blood
pressure and the degree of cardiac hypertrophy were also
Fig. 1. Bar graphs showing the effects of three-week lipoic acid supple-
mentation of 24-hour albuminuria (A ), systolic blood pressure (B ),
and heart weight-to-body weight ratio (C ) in transgenic rats harboring
human renin and human angiotensinogen genes. Lipoic acid completely
prevented the development of angiotensin II (Ang II)-induced albumin-
uria, but only partially decreased blood pressure and ameliorated car-
diac hypertrophy. Abbreviations are: dTGR, double transgenic rats;
LA, lipoic acid; SD, Sprague Dawley rats. dTGR denotes untreated
dTGR; dTGR  LA denotes dTGR supplemented with lipoic acid; SD
denotes normotensive Sprague Dawley controls. Data are mean
SEM.
N  10 in each group. *P  0.05.
markedly higher in dTGR compared to SD rats (Fig. 1
B and C). Lipoic acid completely prevented Ang II–
induced increase in albuminuria. In contrast, lipoic acid
decreased systolic blood pressure only by 34 mm Hg, and
cardiac hypertrophy by 8%. Both systolic blood pressure
and cardiac hypertrophy remained higher in lipoic acid–
supplemented dTGR compared to normotensive SD rats
(P  0.05). In normotensive SD rats, lipoic acid supple-
mentation for 3 weeks slightly but significantly decreased
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Fig. 2. Representative photomicrographs from
the kidneys and heart of untreated dTGR (A
and C ) and dTGR treated with lipoic acid for
three weeks (B and D ). Untreated dTGR kid-
neys show severe glomerular and vascular
damage with mesangial proliferation, glomeru-
lar sclerosis and necrosis, increased intimal and
media thickness, and deposition of matrix. Pro-
found vascular damage with inflammation was
detected in the heart of dTGR. Lipoic acid
prevented angiotensin II (Ang II)–induced
vascular lesions both in the kidney and heart.
Kidney and cardiac damage scores are de-
picted in (E ) and (F ), respectively. dTGR is
double transgenic rat. Data are mean 
 SEM.
N  9 to 10 in each group. *P  0.05. Original
magnification, 200.
blood pressure (114 
 4 mm Hg vs. 128 
 3 mm Hg;
P  0.05), but did not influence cardiac weight-to-body
weight ratio (3.522 
 0.045 mg/g vs. 3.493 
 0.05 mg/g;
P  0.05) or albuminuria (253 
 19 g/day vs. 190 

55 g/day; P  0.05).
Effects of lipoic acid on kidney and heart morphology
Kidneys of untreated dTGR showed severe glomeru-
lar and vascular damage with mesangial proliferation,
glomerular sclerosis and necrosis, increased intimal and
media thickness, and deposition of matrix (Fig. 2, original
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Table 1. Immunohistochemical markers of leukocyte infiltration
(ED1, CD4, CD8) and cell proliferation in dTGR harboring human
renin and angiotensinogen genes, dTGR treated with LA for 3 weeks,
and normotensive SD rats
ANOVA
Variable dTGR dTGR  LA SD P value
ED-1 1.07
0.22a,b 0.26
0.04 0.15
0.05 0.001
CD-4 0.39
0.07a,b 0.13
0.02 0.11
0.01 0.001
CD-8 0.24
0.08a,b 0.17
0.02 0.07
0.02 0.001
PCNA 0.16
0.04a,b 0.03
0.01 0.01
0.01 0.001
Abbreviations are: dTGR, double transgenic rats; LA, lipoic acid; SD, Sprague
Dawley; ANOVA, analysis of variance; PCNA, proliferating cell nuclear antigen.
Values are expressed as the percentage of the immunopositive label per total
surface area. Mean
SEM is given; N  5 to 6 for each group.
aP  0.05 compared to SD; bP  0.05 compared to LA-treated dTGR.
magnification,100). Profound vascular damage with fib-
rinoid necrosis and accumulation of fibronectin (data
not shown) was also observed in the coronary arteries of
dTGR (Fig. 2). Lipoic acid effectively prevented Ang II-
induced vascular lesions both in the kidney (Fig. 2) and
heart (Fig. 2). Renal damage score (Fig. 2) and myocar-
dial damage score (Fig. 2) were markedly decreased by
lipoic acid in dTGR. Lipoic acid supplementation did
not influence either the kidneys or hearts in SD rats
(data not shown).
Effects of lipoic acid on leukocyte infiltration and
cell proliferation
Untreated dTGR showed pronounced leukocyte infil-
tration in the kidneys measured as ED-1, CD-4, and CD-8
immunopositive cells (Table 1). Infiltrated cells were
located predominantly around the damaged vessels. Leu-
kocyte infiltration was less prominent in the heart com-
pared to the kidney (data not shown). Lipoic acid very
effectively prevented inflammatory response in the kid-
neys. In untreated dTGR, the number of PCNA-immu-
nopositive cells in the kidneys was increased by 16-fold.
Lipoic acid attenuated the Ang II–induced cell prolifera-
tion in dTGR.
Effects of lipoic acid on NF-B and AP-1 activation
Nuclear extracts of untreated dTGR showed increased
nuclear factor kappa B (NF-B) and activator protein-1
(AP-1) DNA binding activities in kidney compared to
SD controls (Fig. 3). Lipoic acid inhibited both NF-B
and AP-1 DNA binding activities. Binding specificity
for NF-B was demonstrated by competition of excess
unlabeled oligonucleotides containing the B site from
the MHC-enhancer (H2K). Nuclear extracts were super-
shifted with antibodies against the NF-B subunits p50
and p65. Binding specificity for AP-1 was demonstrated
by competition with excess of unlabeled oligonucleotides
containing the AP-1 site. Complexes were supershifted
with antibodies against c-fos and c-jun. In Figure 3, each
lane represents a separate animal (N 3 in each group).
NF-B and AP-1 DNA binding activities were measured
using separate gels from 6 rats per group. The calculated
mean 
 SEM are depicted as bar graphs in Figure 3.
Effects of lipoic acid on tissue glutathione homeostasis
Transgenic animals had an increased concentration of
glutathione in the kidneys (Fig. 4). On the other hand,
cysteine levels were reduced. Lipoic acid partly pre-
vented renal cysteine depletion. In the liver, lipoic acid
increased both cysteine and glutathione levels. This was
accompanied with an increase in the gammaGCS heavy
subunit mRNA (Fig. 5). Renal gammaGCS mRNA ex-
pression was reduced in dTGR with or without lipoic
acid, suggesting possible control function for oxidized
glutathione.
DISCUSSION
The important finding of the present study is that di-
etary supplementation with lipoic acid protected against
the development of Ang II–induced renal injury. Lipoic
acid prevented Ang II–induced monocyte, macrophage,
and T-cell infiltrations, and also attenuated cell prolifera-
tion in the kidneys. The beneficial effects were associated
with inhibition of transcription factors NF-B and AP-1.
Lipoic acid also improved cellular cysteine supply and
thereby improved tissue thiol homeostasis. Since lipoic
acid partially attenuated the Ang II–induced hyperten-
sion, the renoprotective effects of lipoic acid may also
have been mediated in part by decreased renal hemody-
namic load.
Lipoic acid is a natural antioxidant that scavenges
ROS and regenerates/recycles endogenous antioxidants.
Its metal chelating capacity and its ability to repair oxida-
tive damage contribute to the protective effects [10, 14,
37]. Moini et al [12] have postulated that lipoic acid may
also exert prooxidant properties in vitro. Lipoic acid and
dihydrolipoic acid were shown to promote the mitochon-
drial permeability transition in permeabilized hepato-
cytes and isolated rat liver mitochondria, and to stimulate
superoxide anion production in rat liver mitochondria
and submitochondrial particles. Whether such prooxida-
tive properties of lipoic acid contribute to its versatile
effects observed in vivo remains to be determined. In
cell culture studies lipoic acid effectively inhibits the
DNA binding activity of the redox-sensitive transcrip-
tion factors NF-B and AP-1 [10, 14, 38, 39].
Clark et al [16] used a transient focal central nervous
system ischemic model and showed that pretreatment
with lipoic acid reduced stroke infarct volume and im-
proved neurologic function. Coombes et al [17] demon-
strated that lipoic acid combined with vitamin E pro-
tected the aged rat heart from ischemia/reperfusion
injury and improved cardiac performance. Lipoic acid
produced a modest decrease in blood pressure in our
study. Therefore, the renoprotective benefit found in
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Fig. 3. Activation of DNA binding nuclear factors by Ang II in the
kidney. EMSA for the detection of NF-B and AP-1 showed increased
activities in dTGR kidney compared to SD rats. Lipoic acid inhibited
both NF-B and AP-1. Binding specificity for NF-B was demonstrated
by competition of excess unlabeled oligonucleotides containing the B
site from the MHC-enhancer (H2K). Nuclear extracts were supershifted
with antibodies against the NF-B subunits p50 and p65. Binding speci-
fity for AP-1 was demonstrated by competition with excess unlabeled
Fig. 4. Bar graphs showing the effects of three-week lipoic acid supple-
mentation on liver and kidney cysteine and total glutathione. dTGR
shows increased glutathione (A ) and decreased cysteine concentrations
(B ) in the kidney, but not in the liver (C and D ). Lipoic acid increased
glutathione and cysteine concentrations only in the liver. DTGR is
double transgenic rat. Mean 
 SEM is given. N  6 in each group.
*P  0.05.
dTGR could have been mediated, at least in part, by
blood pressure–dependent mechanisms. However, we
showed previously in dTGR that hydralazine decreased
blood pressure but did not provide any protection against
Ang II–induced renal injury [40]. Furthermore, Ang II
induced leukocyte infiltration and endothelial adhesion
molecule overexpression in the kidneys of dTGR even
when blood pressure was decreased to control levels by
a combination of hydralazine, hydrochlorothiazide, and
reserpine [26]. Vasdev et al [41] showed that lipoic acid
supplementation normalized intracellular calcium con-
oligonucleotides containing the AP-1 site. Complexes were supershifted
with antibodies against c-fos and c-jun. Each lane represents a separate
animal (N 3 in each group). NF-B and AP-1 DNA binding activities
were measured using separate gels from 6 rats per group. The calculated
mean 
 SEM is depicted as a bar graph. Abbreviations are: Ang II,
angiotensin II; EMSA, electrophoretic mobility shift assay; NF-B,
nuclear factor kappa B; AP-1, activator protein-1; dTGR, double trans-
genic rat; SD, Sprague Dawley rat; MHC, major histocompatibility
complex.
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Fig. 5. Bar graphs showing the effects of three-week lipoic acid supple-
mentation on liver and kidney gammaGCS mRNA expressions. Lipoic
acid increased gammaGCS mRNA expression in the liver, but not in the
kidney. dTGR showed decreased renal gammaGCS mRNA expression.
Abbreviations are: GCS, glutamylcysteine synthetase; dTGR, double
transgenic rat. Data shown are mean 
 SEM. N  6 in each group.
*P  0.05.
centration, vascular resistance, and blood pressure in
spontaneously hypertensive rats. Since the kidneys play
a pivotal role in blood pressure regulation, the modest
antihypertensive effect of lipoic acid may have been due
to preserved renal morphology and function. The antihy-
pertensive effect may also be related to scavenging of
superoxide anions. Previous studies have demonstrated a
marked antihypertensive effect by superoxide dismutase
treatment in Ang II–induced hypertension [42]. The
present study also demonstrated that the effects of lipoic
acid on cardiac hypertrophy are likely to be mediated
through decreased pressure overload. We found a close
correlation between blood pressure and the degree of
cardiac hypertrophy in dTGR earlier [43].
NF-B activation can be inhibited by several thiol
antioxidants [38, 39]. Packer et al [10] have previously
shown that lipoic acid suppresses NF-B activation in-
duced by either hydrogen peroxide, phorbol ester, or
tumor necrosis factor- (TNF-) in Wurzburg T cells.
Our study provided in vivo evidence that the beneficial
effects of chronic lipoic acid supplementation are associ-
ated with NF-B and AP-1 inhibition. They support the
notion that activation of these transcription factors was
related to Ang II–induced reactive oxygen species gener-
ation [44].
Lipoic acid is taken up and rapidly reduced to dihy-
drolipoate by lipoamide dehydrogenase, thioredoxin re-
ductase, and glutathione reductase in the presence of
nicotinamide adenine dinucleotide (NADH) or nicotin-
amide adenine dinucleotide phosphate (NADPH) [10, 14].
Dihydrolipoate is then released extracellularly, reduces
cystine to cysteine, and thus promotes glutathione syn-
thesis [39]. We found that dTGR decreased renal cyste-
ine concentrations, whereas the glutathione concentra-
tions were increased. We suggest that Ang II leads either
to increased glutathione production or to decreased con-
sumption. The expression of gammaGCS heavy subunit
was not increased, but this finding does not rule out
changes in posttranscriptional regulation. Further stud-
ies are also needed to determine what happens to GSH.
Lipoic acid increased renal cysteine concentrations, but
had little effect on glutathione. This finding suggests
that lipoic acid cannot compensate for glutathione, but
instead improves the cysteine supply.
CONCLUSION
SD and dTGR rat liver thiol concentrations did not
differ. However, lipoic acid increased cysteine and gluta-
thione levels in the liver. Lipoic acid–induced increases
in hepatic thiol concentrations were accompanied with
a marked up-regulation of gammaGCS gene expression.
Our study agrees with previous reports demonstrating
that glutathione tissue concentrations in the heart and
kidney usually remain unaltered by lipoic acid supple-
mentation [10, 14]. Hence, our findings suggest that the
beneficial effects of lipoic acid against Ang II–induced
end-organ damage is more closely linked to scavenged
ROS and NF-B and AP-1 inhibition rather than direct
changes in the intracellular glutathione concentrations.
Nevertheless, lipoic acid does have a significant effect
on cysteine availability. We were unable to separate the
effects of cysteine, lipoate, glutathione, or other thiols
on oxygen radical scavenging, thiols status, gene expres-
sion, or protein function. We believe that our results
have clinical implications. Lipoic acid may have greater
utility than antioxidant strategies that rely solely on vita-
min E.
Mervaala et al: Lipoic acid and angiotensin II508
ACKNOWLEDGMENTS
This study was supported by grants from the Academy of Finland
and the Sigrid Juse´lius Foundation. We are grateful to Ms. Saara
Merasto and Ms. Sari Laakkonen for expert technical assistance. E.M.
and P.F. contributed equally to this work. The Deutsche Forschungs-
gemeinschaft and the Klinisch-Pharmakologischer Verbund, Berlin-
Brandenburg, supported Dominik N. Mu¨ller.
Reprint requests to Eero Mervaala, M.D., Ph.D., Assistant Professor,
Institute of Biomedicine, Pharmacology, Biomedicum Helsinki, Univer-
sity of Helsinki (Haartmaninkatu 8), FIN-00014, Finland.
E-mail: eero.mervaala@helsinki.fi
REFERENCES
1. Kunsch C, Medford RM: Oxidative stress as a regulator of gene
expression in the vasculature. Circ Res 85:753–766, 1999
2. Griendling KK, Sorescu D, Lasse`gue B, Ushio-Fukai M: Modu-
lation of protein kinase activity and gene expression by reactive
oxygen species and their role in vascular physiology and pathophys-
iology. Arterioscler Thromb Vasc Biol 20:2175–2183, 2000
3. Irani K: Oxidant signalling in vascular cell growth, death, and
survival. A review of the roles of reactive oxygen species in smooth
muscle and endothelial cell mitogenic and apoptotic signalling.
Circ Res 87:179–183, 2000
4. Romero JC, Reckelhoff JF: Role of angiotensin and oxidative
stress in essential hypertension. Hypertension 34:943–949, 1999
5. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase.
Role in cardiovascular biology and disease. Circ Res 86:494–501,
2000
6. Meister A, Anderson ME: Glutathione. Annu Rev Biochem
52:711–760, 1983
7. Meister A: Glutathione metabolism. Methods Enzymol 251:3–7,
1995
8. Anderson ME: Glutathione and glutathione delivery compounds.
Adv Pharmacol 38:65–78, 1997
9. Packer L, Roy S, Sen CK: Alpha-lipoic acid: A metabolic antioxi-
dant and potential redox modulator of transcription. Adv Pharma-
col 38:79–101, 1997
10. Packer L, Witt EC, Tritschler HJ: Alpha-lipoic acid as a biologi-
cal antioxidant. Free Rad Biol Med 19:227–250, 1995
11. Carreau JP: Biosynthesis of lipoic acid via unsaturated fatty acids.
Methods Enzymol 62:152–158, 1979
12. Moini H, Packer L, Saris NE: Antioxidant and prooxidant activi-
ties of alpha-lipoic acid and dihydrolipoic acid. Toxicol Appl Phar-
macol 182:84–90, 2002
13. Morikawa T, Yasuno R, Wada H: Do mammalian cells synthesize
lipoic acid? Identification of a mouse cDNA encoding a lipoic acid
synthase located in the mitochondria. FEBS Lett 498:16–21, 2001
14. Sen CK, Packer L: Thiol homeostasis and supplements in physical
exercise. Am J Clin Nutr 72(Suppl 2):653S–659S, 2000
15. Sen CK, Packer L: Antioxidant and redox regulation of gene
transcription. FASEB J 10:709–720, 1996
16. Clark WM, Rinker LG, Lessov NS, et al: Efficacy of antioxidant
therapies in transient focal ischemia in mice. Stroke 32:1000–1004,
2001
17. Coombes JS, Powers SK, Hamilton KL, et al: Improved cardiac
performance after ischemia in aged rats supplemented with vitamin
E and -lipoic acid. Am J Physiol Regul Integr Comp Physiol
279:R2149–R2155, 2000
18. Hagen TM, Ingersoll RT, Lykkesfeldt J, et al: (R)--Lipoic
acid-supplemented old rats have improved mitochondrial function,
decreased oxidative damage, and increased metabolic rate. FASEB
J 13:411–418, 1999
19. Suh JH, Shigeno ET, Morrow JD, et al: Oxidative stress in the
aging rat heart is reversed by dietary supplementation with (R)-
-lipoic acid. FASEB J 15:700–706, 2001
20. Kocak G, Aktan F, Canbolat O, et al: Alpha-lipoic acid treatment
ameliorates metabolic parameters, blood pressure, vascular reac-
tivity and morphology of vessels already damaged by streptozo-
tocin-diabetes. Diabetes Nutr Metab 13:308–318, 2000
21. Melhem MF, Craven PA, Liachenko J, DeRubertis FR: Alpha-
lipoic acid attenuates hyperglycemia and prevents glomerular mes-
angial matrix expansion in diabetes. J Am Soc Nephrol 13:108–116,
2000
22. El Midaoui A, de Champlain J: Prevention of hypertension, insu-
lin resistance, and oxidative stress by alpha-lipoic acid. Hyperten-
sion 39:303–307, 2002
23. Takaoka M, Kobayashi Y, Yuba M, et al: Effects of alpha-lipoic
acid on deoxycorticosterone acetate-salt-induced hypertension in
rats. Eur J Pharmacol 424:121–129, 2001
24. Luft FC, Mervaala EMA, Muller DN, et al: Hypertension-
induced end-organ damage. A new transgenic approach to an old
problem. Hypertension 33:212–218, 1999
25. Mervaala EMA, Muller DN, Park J-K, et al: Monocyte infiltra-
tion and adhesion molecules in a rat model of high human renin
hypertension. Hypertension 33:389–395, 1999
26. Mervaala EMA, Muller DN, Schmidt F, et al: Blood pressure-
independent effects in rats with human renin and angiotensinogen
genes. Hypertension 35:587–594, 2000
27. Mu¨ller DN, Dechend R, Mervaala EMA, et al: NF-kappaB
inhibition ameliorates angiotensin II-induced inflammatory dam-
age in rats. Hypertension 35:193–201, 2000
28. Mervaala EMA, Cheng ZJ, Tikkanen I, et al: Endothelial dys-
function and xanthine oxidoreductase activity in rats with human
renin and angiotensinogen genes. Hypertension 37:414–418, 2001
29. Ganten D, Wagner J, Zeh K, et al: Species specificity of renin
kinetics in transgenic rats harboring human renin and angiotensino-
gen genes. Proc Natl Acad Sci USA 89:7806–7810, 1992
30. Bohlender J, Fukamizu A, Lippoldt A, et al: High human renin
hypertension in transgenic rats. Hypertension 29:428–434, 1997
31. Lykkesfeldt J, Hagen TM, Vinarsky V, Ames BN: Age-associ-
ated decline in ascorbic acid concentration, recycling, and biosyn-
thesis in rat hepatocytes—Reversal with (R)--lipoic acid supple-
mentation. FASEB J 12:1183–1189, 1998
32. Pere A-K, Lindgren L, Tuomainen P, et al: Dietary potassium
and magnesium supplementations in cyclosporine-induced hyper-
tension and nephrotoxicity. Kidney Int 58:2462–2472, 2000
33. Finckenberg P, Lassila M, Inkinen K, et al: Cyclosporine A
induces myocardial connective tissue growth factor in spontane-
ously hypertensive rats on high sodium diet. Transplantation 71:
951–958, 2001
34. Muller DN, Dechend R, Mervaala EMA, et al: NF-kappaB
inhibition ameliorates angiotensin II-induced inflammatory dam-
age in rats. Hypertension 35:193–201, 2000
35. Levonen AL, Laakso J, Vaskonen T, et al: Down-regulation of
renal glutathione synthesis by systemic nitric oxide synthesis inhibi-
tion in spontaneously hypertensive rats. Biochem Pharmacol 59:
441–443, 2000
36. Levonen AL, Lapatto R, Saksela M, Raivio KO: Expression of
gamma-glutamylcysteine synthetase during development. Pediatr
Res 47:266–270, 2000
37. Biewenga GP, Haenen GR, Bast A: The pharmacology of the
antioxidant lipoic acid. Gen Pharmacol 29:315–331, 1997
38. Sen CK, Packer L: Antioxidant and redox regulation of gene
transcription. FASEB J 10:709–720, 1996
39. Sen CK: Redox signaling and the emerging therapeutic potential
of thiol antioxidants. Biochem Pharmacol 55:1747–1758, 1998
40. Muller DN, Mervaala EMA, Schmidt F, et al: Effect of bosentan
on NF-kB, inflammation, and tissue factor in angiotensin II-
induced end-organ damage. Hypertension 36:282–290, 2000
41. Vasdev S, Ford CA, Parai S, et al: Dietary-lipoic acid supplemen-
tation lowers blood pressure in spontaneously hypertensive rats.
J Hypertens 18:567–573, 2000
42. Laursen JB, Rajagopalan S, Galis Z, et al: Role of superoxide
in angiotensin II-induced but not catecholamine-induced hyperten-
sion. Circulation 95:588–593, 1997
43. Mervaala EMA, Dehmel B, Gross V, et al: ACE inhibition and
AT1 receptor blockade modify pressure-natriuresis by different
mechanisms in rats with human renin and angiotensinogen genes.
J Am Soc Nephrol 10:1669–1680, 1999
44. Dzau V: Tissue angiotensin and pathobiology of vascular disease.
A unifying hypothesis. Hypertension 37:1047–1052, 2001
